Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

106.00GBp
15 Dec 2017
Change (% chg)

-6.00 (-5.36%)
Prev Close
112.00
Open
111.60
Day's High
111.80
Day's Low
100.60
Volume
9,551,557
Avg. Vol
2,258,677
52-wk High
166.97
52-wk Low
86.50

Latest Key Developments (Source: Significant Developments)

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 

Vectura Group Plc : Update on Mundipharma's European Phase III trial of flutiform ® in COPD and latest flutiform ® in-market sales . Informed by its partner mundipharma that its phase iii trial of flutiform ® did not meet primary endpoint . Mundipharma is currently undertaking an analysis of trial's other endpoints .Mundipharma has indicated that primary endpoint result will not allow it to make a regulatory filing for COPD indication in Europe.  Full Article

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 

Vectura Group Plc : Has been informed by its partner Mundipharma that its phase III trial of flutiform® did not meet primary endpoint .Mundipharma is currently undertaking an analysis of trial's other endpoints but has indicated that primary endpoint result will not allow it to make a regulatory filing for copd indication in europe..  Full Article

Vectura initiates legal proceedings against GSK in the U.S.
Wednesday, 27 Jul 2016 

Vectura Group Plc : Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK) . Vectura has filed a patent infringement lawsuit against GSK claiming infringement of Vectura's U.S. patents in Delaware district court . Continues to remain open to finding a mutually acceptable solution in order to avoid costs and potential uncertainty over royalties that have, up to now, been subject to a cap of 13 mln stg per calendar year . Separate licence agreement with GSK relating to legacy Skyepharma dry powder formulation technology used in Ellipta products is unaffected .Despite notification from GSK, directors believe that revenues for current financial year ending December 2016 remain in line with current expectations.  Full Article

Vectura says Ablynx to exercise a license option on Fox device
Tuesday, 28 Jun 2016 

Vectura Group Plc :Ablynx to exercise option to license Vectura's Fox device for use in its forthcoming phase IIB efficacy study of its inhaled anti-rsv nanobody.  Full Article

Skyepharma sayas High Court of Justice sanctions scheme on merger
Thursday, 9 Jun 2016 

Skyepharma Plc :High court of justice in england and wales made an order sanctioning scheme on merger with vectura.  Full Article

Vectura FY core earnings rise 43 pct
Thursday, 26 May 2016 

Vectura Group Plc : FY revenues up 24% to £72.0m (2014/15: £58.0m) .EBITDA(1) up 43% to £23.2m (2014/15: £16.2m).  Full Article

Vectura & Propeller Health announce collaboration
Tuesday, 24 May 2016 

Vectura Group Plc : Vectura & propeller health announce collaboration .Vectura and propeller health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases.  Full Article

Skyepharma sees strong growth in 2016 revenues
Wednesday, 18 May 2016 

Skyepharma Plc : Board continues to expect strong growth in revenues for full year 2016 compared with 2015 .Overall trading performance to end of April has been good.  Full Article

Vectura Group says CMA not to investigate Vectura-Skyepharma merger
Monday, 16 May 2016 

Vectura Group Plc : CMA has confirmed that proposed recommended all share merger of Vectura and Skyepharma does not qualify for investigation .Confirmation satisfies CMA clearance condition to implementation of proposed merger.  Full Article

UK's CMA says no relevant merger situation in Vectura-Skyepharma deal
Monday, 16 May 2016 

Competitions and Markets Authority :UK's CMA says decided that a relevant merger situation has not been created in anticipated acquisition by Vectura Group Plc of Skyepharma Plc.  Full Article

BRIEF-Vectura group announces buyback to return up to £15 million of capital to shareholders​

* ‍vectura group plc (lse: vec) ("vectura", " group"), announces that board has approved a share buyback to return up to £15 million of capital to shareholders​ Source text for Eikon: Further company coverage: (Reporting by Lawrence White)